Biotech, Roundup, cancer
Zymo Boss Sees Immunex Parallel, Arch Startup Bags $7M, Northstar Folds, & More Seattle-Area Life Sciences News
Luke Timmerman 1/8/09
(Page 2 of 2)
about a huge effort at the University of Washington, Fred Hutchinson Cancer Research Center, and Seattle Children’s Hospital funded by the National Institutes of Health. The goal is to translate basic science discoveries into tangible new drugs or devices that help patients. This sounds great, but herding all the various cats in academic labs with industrial drug developers is no small feat.
—We did a feature on an intriguing Seattle-based company, Qliance, that doesn’t plan to develop a breakthrough drug, but hopes it can foster a revolution in how health care is delivered to the consumer by sidestepping insurers.
—Sunnyvale, CA-based Cepheid (NASDAQ: CPHD) hasn’t gotten much press in Washington state, but we got the inside scoop about why this fast-growing molecular diagnostics company is planning to grow its presence in Bothell.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
